Skip to main content
Contact Us
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
CDMO Intelligence
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Neovacs
Evaluate
August 31, 2018
After Astra’s failure lupus attention turns to Aurinia
July 03, 2018
Beleaguered Neovacs still has it all to do
June 15, 2017
Therapy focus – Lupus hopes build but data remain on the distant horizon
July 06, 2015
Interview – US placement reanimates Neovacs into lupus play
January 08, 2015
Buoyant small pharma market hides some big losers
December 24, 2014
Cyclacel and Neovacs enter the graveyard shift
October 29, 2012
Therapeutic focus – Roche and AstraZeneca take interferon approach to lupus
January 16, 2012
IPO hopefuls line up after woeful 2011
November 25, 2011
EP Vantage Interview - Neovacs seeking partners for autoimmune vaccines
July 12, 2011
Tough IPO scene continues in first half 2011
Latest Reports
July 27, 2023
H1 Round Up: The haves and the have-nots
July 21, 2023
ADA/EASL eBook
Editor's Picks
July 03, 2023
Astrazeneca and Daiichi’s big reveal disappoints
July 13, 2023
Pharma finds a way to gain weight
July 03, 2023
Protagonist investors flake as psoriasis pill disappoints
June 29, 2023
Approaching datasets for big pharma
June 27, 2023
Nkarta goes back to basics